Beneficial Ownership Report · SCHEDULE 13G
OnKure Therapeutics, Inc.
OKURNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- OnKure Therapeutics, Inc.
- Company CIK
- 0001637715
- Street
- 6707 Winchester Circle, #400
- City
- Boulder
- State / country code
- CO
- Postal code
- 80301
Statement details
- Security class
- Class A Common Stock, par value $0.0001 per share
- Event date
- 11/13/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Venrock Healthcare Capital Partners III, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- a
- Aggregate amount owned
- 2,309,559.00
- Percent of class
- 5.7
- Sole voting power
- 0.00
- Shared voting power
- 2,309,559.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,309,559.00
Reporting person 2
- Name
- VHCP Co-Investment Holdings III, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 2,309,559.00
- Percent of class
- 5.7
- Sole voting power
- 0.00
- Shared voting power
- 2,309,559.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,309,559.00
Reporting person 3
- Name
- Venrock Healthcare Capital Partners EG, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- a
- Aggregate amount owned
- 2,309,559.00
- Percent of class
- 5.7
- Sole voting power
- 0.00
- Shared voting power
- 2,309,559.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,309,559.00
Reporting person 4
- Name
- VHCP Management III, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 2,309,559.00
- Percent of class
- 5.7
- Sole voting power
- 0.00
- Shared voting power
- 2,309,559.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,309,559.00
Reporting person 5
- Name
- VHCP Management EG, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 2,309,559.00
- Percent of class
- 5.7
- Sole voting power
- 0.00
- Shared voting power
- 2,309,559.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,309,559.00
Reporting person 6
- Name
- Nimish Shah
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- a
- Aggregate amount owned
- 2,309,559.00
- Percent of class
- 5.7
- Sole voting power
- 0.00
- Shared voting power
- 2,309,559.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,309,559.00
Reporting person 7
- Name
- Bong Y. Koh
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- a
- Aggregate amount owned
- 2,309,559.00
- Percent of class
- 5.7
- Sole voting power
- 0.00
- Shared voting power
- 2,309,559.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,309,559.00
Item 1
Issuer
OnKure Therapeutics, Inc.
Principal executive office address
6707 Winchester Circle, #400, Boulder, CO, 80301.
Item 2
Citizenship
All of the entities were organized in Delaware. Shah and Koh are both United States citizens.
Filing person
The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish P. Shah ("Shah") Bong Y. Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G.
Principal business or residence address
New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304
Item 3
Not applicable indication
Y
Item 4
Percent of class
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of the shares of Class A common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based upon 40,503,094 shares of Class A common stock outstanding as of Noember 2, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 4, 2026.
Amount beneficially owned
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Class A common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 1,049,696 shares of Class A common stock held by VHCP III, (ii) 105,087 shares of Class A common stock held by VHCP Co-Investment III, and (iii) 1,154,776 shares of Class A common stock held by held by VHCP EG. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
Sole voting power
Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Shared voting power
Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Sole dispositive power
Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Shared dispositive power
Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 24.1 Power of Attorney for Bong Y. Koh Exhibit 24.2 Power of Attorney for Nimish P. Shah Exhibit 99.1 Joint Filing Agreement
Signature 1
- Reporting person
- Venrock Healthcare Capital Partners III, L.P.
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
- Date
- 11/20/2026
Signature 2
- Reporting person
- VHCP Co-Investment Holdings III, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
- Date
- 11/20/2026
Signature 3
- Reporting person
- Venrock Healthcare Capital Partners EG, L.P.
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
- Date
- 11/20/2026
Signature 4
- Reporting person
- VHCP Management III, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Authorized Signatory
- Date
- 11/20/2026
Signature 5
- Reporting person
- VHCP Management EG, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Authorized Signatory
- Date
- 11/20/2026
Signature 6
- Reporting person
- Nimish Shah
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Attorney-in-fact
- Date
- 11/20/2026
Signature 7
- Reporting person
- Bong Y. Koh
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Attorney-in-fact
- Date
- 11/20/2026
Filed exhibits
- POWER OF ATTORNEY FOR BONG Y. KOH ↗ex-24-11202026_101145.htm
- POWER OF ATTORNEY FOR NIMISH P. SHAH ↗ex-24-11202026_101146.htm
- JOINT FILING AGREEMENT ↗ex-99-11202026_101147.htm
Company context
OnKure Therapeutics (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of vascular anomalies and cancers that are underserved by available therapies. Using a structure and computational chemistry-driven drug design platform, OnKure is committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of vascular anomalies and cancer. OnKure aims to become a leader in targeting PI3Kα and has multiple programs designed to enable best-in-class targeting of this important molecular target.
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by BIOTECHNOLOGY VALUE FUND L P regarding OnKure Therapeutics, Inc.Nov 16, 2026
- Results of Operations and Financial ConditionNov 4, 2026
- 10-Q filingNov 4, 2026
- 4 filingSep 23, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 13, 2026